{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T07:14:32Z","timestamp":1655277272025},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.lpm.2016.02.005","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T15:01:19Z","timestamp":1458140479000},"page":"350-359","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["D\u00e9pression r\u00e9sistante\u00a0: les autres strat\u00e9gies th\u00e9rapeutiques"],"prefix":"10.1016","volume":"45","author":[{"given":"Ghassen","family":"Saba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Bation","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najib","family":"Alla\u00efli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djamila","family":"Bennabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Moliere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00eblle","family":"Richieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Holtzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Bubrovszky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Camus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Charpeaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Courtet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Courvoisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Haesebaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Doumy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissam","family":"El-Hage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"d\u2019Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Bougerol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Lan\u00e7on","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Haffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Michel","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Vaiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Bellivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Leboyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Aouizerate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2016.02.005_bib0360","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40263-013-0097-3","article-title":"Current place of monoamine oxidase inhibitors in the treatment of depression","volume":"27","author":"Shulman","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.lpm.2016.02.005_bib0365","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","article-title":"Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release","volume":"143","author":"Finberg","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.lpm.2016.02.005_bib0370","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/archpsyc.63.11.1209","article-title":"Elevated monoamine oxidase A level in the brain","volume":"63","author":"Meyer","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0375","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archgenpsychiatry.2009.156","article-title":"Brain monoamine oxidase A binding in major depressive disorders","volume":"66","author":"Meyer","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.005_bib0380","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4088\/JCP.11096su1c.03","article-title":"Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update","volume":"73","author":"Flockhart","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0385","series-title":"Practice guideline for the treatment of patients with major depressive disorders","author":"American Psychiatric Association","year":"2010"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.005_bib0390","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jad.2009.06.041","article-title":"Canadian Network for Mood an Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorders in adults. III. Pharmacotherapy","volume":"117","author":"Lam","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.005_bib0395","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0447.2009.01492.x","article-title":"An algorithm for the pharmacological treatment of depression","volume":"121","author":"Spijker","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.lpm.2016.02.005_bib0400","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0405","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/ajp.150.1.118","article-title":"A double blind cross-over trial of imipramine and phenelzine for outpatients with treatment-refractory depression","volume":"150","author":"McGrath","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0410","first-page":"5","article-title":"Treatment of imipramine resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors","volume":"53","author":"Thase","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0415","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1192\/bjp.bp.111.102665","article-title":"Prediction of longer outcome of treatment-resistant depression in tertiary care","volume":"201","author":"Fekadu","year":"2012","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0420","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1176\/appi.ajp.2012.12060754","article-title":"Monoamine oxidase inhibitors potentiate the effect of deep brain stimulation","volume":"169","author":"Hamani","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.lpm.2016.02.005_bib0425","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00004714-199508001-00005","article-title":"Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double blind, parallel, multicenter study","volume":"15","author":"Kragh-S\u00f8rensen","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.005_bib0430","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0022-3956(96)00030-1","article-title":"Moclobemide versus fluoxetine for double depression: a randomized double-blind study","volume":"30","author":"Duarte","year":"1996","journal-title":"J Psychiatr Res"},{"issue":"4","key":"10.1016\/j.lpm.2016.02.005_bib0435","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00004714-199508001-00008","article-title":"A double blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression","volume":"15","author":"Stabl","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.005_bib0440","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0165-0327(94)90081-7","article-title":"Brofaromine in treatment resistant depressed patients\u2013a comparative trial versus tranylcypromine","volume":"30","author":"Voltz","year":"1994","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.005_bib0445","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0893-133X(98)00075-X","article-title":"Meta-analysis of the reversible inhibitors of monoamine oxydase type A moclobemide and brofaromine for the treatment of depression","volume":"3","author":"Lotufo-Neto","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lpm.2016.02.005_bib0450","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0165-0327(95)00034-K","article-title":"Therapeutic efficacy of antidepressants in agitated anxious depression\u2013a meta-analysis of moclobemide studies","volume":"35","author":"Delini-Satula","year":"1995","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.005_bib0455","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","article-title":"Transdermal selegiline in major depression: a double blind, placebo-controlled, parallel group study in outpatients","volume":"159","author":"Bodkin","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0460","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4088\/JCP.v64n0216","article-title":"A double blind, placebo-controlled, trial of the safety of selegiline transdermal system without dietary restrictions in patients with major depressive disorder","volume":"64","author":"Amsterdam","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0465","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.4088\/JCP.v67n0905","article-title":"Selegiline transdermal system for the treatment of major depressive disorders: an 8-week double blind, placebo-controlled flexible dose titration trial","volume":"67","author":"Feiger","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0470","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01.jcp.0000239794.37073.70","article-title":"Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week double blind, placebo substitution, parallel group clinical trial","volume":"26","author":"Amsterdam","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.005_bib0475","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/mp.2012.25","article-title":"Eicosapentaenoic acid appears to be the key omega-3\u00a0fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis","volume":"17","author":"Martins","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0480","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/mp.2011.100","article-title":"Omega-3\u00a0fatty acids for the treatment of depression: systematic review and meta-analysis","volume":"17","author":"Bloch","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0485","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archpsyc.59.10.913","article-title":"A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs","volume":"59","author":"Peet","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0490","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/appi.ajp.159.3.477","article-title":"Addition of omega-3\u00a0fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder","volume":"159","author":"Nemets","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.005_bib0495","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jad.2009.06.040","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments","volume":"117","author":"Ravindran","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.005_bib0500","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000151527","article-title":"Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes","volume":"15","author":"Resler","year":"2008","journal-title":"Neurimmunomodulation"},{"key":"10.1016\/j.lpm.2016.02.005_bib0505","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0165-0327(00)00153-1","article-title":"Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial","volume":"60","author":"Coppen","year":"2000","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.005_bib0510","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/07315724.1992.12098238","article-title":"Brief communication. Vitamin B1, B2, and B6\u00a0augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction","volume":"11","author":"Bell","year":"1992","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.lpm.2016.02.005_bib0515","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0140-6736(90)91942-4","article-title":"Enhancement of recovery from psychiatric illness by methylfolate","volume":"336","author":"Godfrey","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2016.02.005_bib0520","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1176\/appi.ajp.2012.11071114","article-title":"L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials","volume":"169","author":"Papakostas","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0525","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-nutr-071811-150659","article-title":"Lessons learned from randomized clinical trials of micronutrient supplementation for cancer prevention","volume":"21","author":"Mayne","year":"2012","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.lpm.2016.02.005_bib0530","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4088\/JCP.13m08947","article-title":"Effect of adjunctive l -methylfolate 15mg among inadequate responders to ssris in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial","volume":"75","author":"Papakostas","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0535","first-page":"1","article-title":"S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease","volume":"64","author":"Hardy","year":"2003","journal-title":"Evid Rep Technol Assess"},{"key":"10.1016\/j.lpm.2016.02.005_bib0540","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1017\/S1461145702003085","article-title":"A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder","volume":"5","author":"Pancheri","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.005_bib0545","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0165-1781(95)02656-H","article-title":"Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine","volume":"56","author":"Fava","year":"1995","journal-title":"Psychiatr Res"},{"key":"10.1016\/j.lpm.2016.02.005_bib0550","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0165-1781(92)90029-3","article-title":"Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine","volume":"44","author":"Berlanga","year":"1992","journal-title":"Psychiatr Res"},{"key":"10.1016\/j.lpm.2016.02.005_bib0555","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.11m07139","article-title":"Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder","volume":"73","author":"Mischoulon","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0560","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000288642","article-title":"Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women","volume":"59","author":"Salmaggi","year":"1993","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.lpm.2016.02.005_bib0565","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1176\/ajp.147.5.591","article-title":"Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial","volume":"147","author":"Kagan","year":"1990","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0570","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1600-0447.1990.tb05476.x","article-title":"The antidepressant potential of oral S-adenosyl-l-methionine","volume":"81","author":"Rosenbaum","year":"1990","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.lpm.2016.02.005_bib0575","doi-asserted-by":"crossref","first-page":"1172S","DOI":"10.1093\/ajcn\/76.5.1172S","article-title":"Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2\u00a0multicenter studies","volume":"76","author":"Delle Chiaie","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.lpm.2016.02.005_bib0580","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4088\/JCP.13m08591","article-title":"A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder","volume":"75","author":"Mischoulon","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0585","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/appi.ajp.2009.09081198","article-title":"S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial","volume":"67","author":"Papakostas","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0590","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1592\/phco.24.16.1501.50943","article-title":"Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans","volume":"24","author":"G\u00f6ren","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.lpm.2016.02.005_bib0595","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.eurpsy.2011.01.003","article-title":"SAMe and sexual functioning","volume":"27","author":"Dording","year":"2012","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0600","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archpsyc.64.2.193","article-title":"Reduced prefrontal glutamate\/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy","volume":"64","author":"Hasler","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0605","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/mp.2011.23","article-title":"Discovering imaging endophenotypes for major depression","volume":"16","author":"Hasler","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0610","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.12223","article-title":"New paradigms for treatment-resistant depression","volume":"1292","author":"Zarate","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.lpm.2016.02.005_bib0615","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0620","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate-antagonist in treatment resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0625","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0630","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"Aan Het Rot","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0635","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0640","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.005_bib0645","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lpm.2016.02.005_bib0650","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine for depression: where do we go from here?","volume":"72","author":"Aan Het Rot","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0655","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/YCT.0b013e3181c3b0aa","article-title":"Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and profofol anesthesia","volume":"26","author":"Okamoto","year":"2010","journal-title":"J ECT"},{"key":"10.1016\/j.lpm.2016.02.005_bib0660","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2011.03.019","article-title":"Rapid decrease in depressive symptoms with an N-methyl-D-aspartate Antagonist in ECT-resistant major depression","volume":"35","author":"Ibrahim","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0665","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4088\/JCP.v64n0911","article-title":"Adjunct modafinil for the short-term treatment for fatigue and sleepiness in patients with major depressive disorder: a preliminary double-bind, placebo-controlled study","volume":"64","author":"DeBattista","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0670","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4088\/JCP.v66n0112","article-title":"A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness","volume":"66","author":"Fava","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0675","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/01.jcp.0000246212.03530.fd","article-title":"A randomized, double-blind, placebo controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression","volume":"26","author":"Paktar","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.02.005_bib0680","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4088\/JCP.v69n0112","article-title":"Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double blind, randomized placebo controlled trial","volume":"69","author":"Ravindran","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0685","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, fluoxetine, and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.lpm.2016.02.005_bib0690","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4088\/JCP.12m08093","article-title":"A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder","volume":"74","author":"Cusin","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0695","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jad.2012.06.022","article-title":"Total sleep deprivation followed by sleep phase advance and bright light therapy in drug-resistant mood disorders","volume":"144","author":"Echizenya","year":"2013","journal-title":"J Affect Disord"},{"key":"10.1016\/j.lpm.2016.02.005_bib0700","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4088\/JCP.10m06743","article-title":"Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison","volume":"72","author":"Trivedi","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2016.02.005_bib0705","series-title":"Psychostimulants for depression (review)","author":"Candy","year":"2009"},{"key":"10.1016\/j.lpm.2016.02.005_bib0355","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00023210-200721030-00004","article-title":"Psychostimulants in the treatment of depression","volume":"21","author":"Orr","year":"2007","journal-title":"CNS Drugs"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549821600066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549821600066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T06:30:32Z","timestamp":1655274632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075549821600066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S075549821600066X"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2016.02.005","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9pression r\u00e9sistante\u00a0: les autres strat\u00e9gies th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}